Latest Industry Insights

James Connelly discusses the importance of third-party verification and how recent funding will help accelerate the development of Impact Laboratories' digital sustainability tools.

Technology Networks spoke with Dr. Irina Babina, chief executive officer of Concr, to explore the origins of the company, the science behind its platform and the tangible impact it hopes to deliver for patients and healthcare systems alike.

Technology Networks spoke with Dr. Jenny Bailey Cooper, co-founder and CEO of Ferryx, to learn the science behind its lead product, Ferrocalm^TM, and how its innovative strategy could reshape the future of gut health.

Portal Bio’s microfluidic technology enhances drug discovery and cell engineering by enabling efficient, scalable molecular delivery for sensitive cell types.

At the BioTrinity 2025 conference, Technology Networks spoke with Dr. Pedro Correa de Sampaio, co-founder and CEO of Neobe, who are utilizing synthetic biology to engineer bacteria capable of breaking down the barriers within tumors.

In this article, Technology Networks spoke with Dr. Jack Hoppin and Dr. John Babich from Ratio Therapeutics to learn more about the recent radiopharmaceutical revolution.

To explore how PROTACs are transforming drug discovery, we spoke with Robyn Stoller, business development manager at Cytiva.

In this interview, Technology Networks spoke with Dr. Lena Jonsson, product strategy manager at Cytiva, to explore the biological, clinical and technological frontiers shaping the next generation of ADCs.

Technology Networks spoke to Jason Barker, ND, clinical lab educator at Vibrant Wellness, to explore why co-infections from tick bites are frequently underdiagnosed and to examine current and future testing protocols of tick-borne diseases.

In this interview, Technology Networks spoke with Dr. Francesco Dell’Accio and Dr. Suzanne Eldridge to explore the impact of osteoarthritis on patients, the goals of ReFleks and a novel approach to repairing osteochondral defects.